Citi added a “30-day upside catalyst watch” on shares of Dummit Therapeutics while keeping a Buy rating on the name with a $35 price target The firm sees the stock moving higher on HARMONi-6 presentation scheduled for October 19.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics initiated with an Underweight at Barclays
- Summit Therapeutics’ Ivonescimab Shows Promising Trial Results, Offering a Risk-Mitigation Opportunity with a Buy Rating
- Biotech Alert: Searches spiking for these stocks today
- Summit Therapeutics falls -24.1%
- EchoStar sells spectrum licenses to SpaceX, StubHub to launch IPO: Morning Buzz